medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2018-4-86-89medsovet-2338Research ArticleДРУГИЕ ПРОБЛЕМЫ ЭНДОКРИНОЛОГИИOTHER PROBLEMS OF ENDOCRINOLOGYЭффективность терапии лираглутидом 3 мг при лечении ожирения и ассоциированных с ним заболеванийEfficacy of liraglutide 3 mig therapy in obesity and associated diseasesКомшиловаК. А.KomshilovaK. A.

Кандидат медицинских наук 

Москва

PhD in medicine 

Moscow

ТрошинаЕ. А.TroshinaE. A.

Член-корреспондент РАН, доктор медицинских наук, профессор

Москва

Corr. Member of RAS, MD, Prof.

Moscow

 

Национальный медицинский исследовательский центр эндокринологии Минздрава РоссииРоссияNational Medical Research Centre of Endocrinology of the Ministry of Health of RussiaRussian Federation201831032018048689Copyright © Комшилова К.А., Трошина Е.А., 20182018Комшилова К.А., Трошина Е.А.Komshilova K.A., Troshina E.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/2338

Ожирение – хроническое заболевание, ассоциированное с кардиометаболическими факторами риска, в первую очередь сердечно-сосудистыми заболеваниями и сахарным диабетом 2-го типа. В2016 г. в России зарегистрирован новый препарат для лечения пациентов с ожирением лираглутид 3,0 мг, являющийся аналогом человеческого глюкагоноподобного пептида-1. Учитывая актуальность проблемы, приводим клинический случай, демонстрирующий эффективность терапии лираглутидом 3,0 мг/сут у пациентки с ожирением и его влияние на метаболические факторы риска.

Obesity is a chronic disease associated with cardiometabolic risk factors, primarily cardiovascular diseases and type 2 diabetes mellitus. In 2016,Russiaregistered a new drug for treating obese patients liraglutide 3.0 mg, which is an analogue of human glucagon-like peptide-1. Given the urgency of the problem, we present a clinical case that shows the efficacy of therapy with liraglutide 3.0 mg daily in a patient with obesity, and its effect on metabolic risk factors.

ожирениелираглутид 30 мг/сутаналог человеческого глюкагоноподобного пептида-1obesityliraglutide 3.0 mg once dailyanalogue of human glucagon-like peptide-1Компания «Ново Нордиск».ReferencesWorld Health Organization. Obesity: preventing and managing the global epidemic. Geneva, Switzerland: World Health Organization, 1998.World Health Organization. Obesity: preventing and managing the global epidemic. Geneva, Switzerland: World Health Organization, 1998.Bosello O and Zamboni M. Visceral obesity and metabolic syndrome. Obesity reviews? 2000, 1: 47-56.Bosello O and Zamboni M. Visceral obesity and metabolic syndrome. Obesity reviews? 2000, 1: 47-56.Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L, INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet, 2004, 364(9438): 937–52. doi: 10.1016/S0140-6736(04)17018-9.Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L, INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet, 2004, 364(9438): 937–52. doi: 10.1016/S0140-6736(04)17018-9.Jensen MD, Ryan MD, Donato SM, et al. Executive summary: Guidelines (2013) for the management of оverweight and obesity in adults. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society Published by The Obesity Society and American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Based on a systematic review from the The Obesity Expert Panel, 2013. Obesity (Silver Spring), 2014, 22(suppl 2): 5-39.Jensen MD, Ryan MD, Donato SM, et al. Executive summary: Guidelines (2013) for the management of оverweight and obesity in adults. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society Published by The Obesity Society and American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Based on a systematic review from the The Obesity Expert Panel, 2013. Obesity (Silver Spring), 2014, 22(suppl 2): 5-39.Astrup A, Carraro R, Finer N, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond), 2013 Feb, 37(2): 322.Astrup A, Carraro R, Finer N, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond), 2013 Feb, 37(2): 322.Dombrowski SU, Knittle K, et al. Long term maintenance of weight loss with non-surgical interventions in obese adults: systematic review and meta-analyses of randomised controlled trials. BMJ, 2014, 348: 2646.Dombrowski SU, Knittle K, et al. Long term maintenance of weight loss with non-surgical interventions in obese adults: systematic review and meta-analyses of randomised controlled trials. BMJ, 2014, 348: 2646.Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond), 2013 Nov, 37(11): 1514.Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond), 2013 Nov, 37(11): 1514.

The authors declare that there are no conflicts of interest present.